Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
305.06
-5.21 (-1.68%)
At close: Nov 17, 2026, 4:00 PM EST
307.00
+1.94 (0.64%)
After-hours: Nov 17, 2026, 7:30 PM EST
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 16, 2026

Summary

Management expressed high confidence ahead of Ulixacaltamide’s January 29 PDUFA and described a broad expected label, durable benefit and a controlled launch strategy. Relutrigine and several pipeline programs offer additional near-term catalysts.

Joon Lee
Biotech Analyst, UBS

Okay. Well, thank you everyone for joining us for this inaugural UBS Global Biopharma Conference. My name is Joon Lee, one of the biotech analysts here. For this session, we have Marcio Souza, CEO of Praxis. Marcio, thank you so much for joining us for the fireside chat. You have arguably the most consequential biotech catalyst, the January 29 PDUFA for ulixacaltamide, and you have two more before that. I mean, the bases are loaded. To prepare for all this, you hosted an investor event detailing how you will be the preeminent neurology franchise, even exceeding that of some of the pharmas. Praxis is a relatively new stock coverage for UBS, and for the audience who may be new to the story, just tell us a little bit about Praxis, where you are, and why it matters for the investors.

Marcio Souza
CEO, Praxis Precision Medicines

I think where we are is two NDAs in front of us, 21 programs, and I know the audience is going to want to talk a lot about Ulixa. Incredibly excited about that, as you can imagine, with the NDA approval coming in, and I'm even saying approval because I think that's really the stage we're in right now in January. There is not a lot of times in life that you come with a drug that 9 million Americans, many, many million outside of the U.S. suffer from, and there's really nothing—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—from them. For more than I would like to talk about the entire portfolio, and I'll be happy to talk about that, and I'm sure Tim and Megan and John, who are here with me, could do that as well. With incredible respect to everything else we're doing and to the needs of these patients, when you think about the scale of the company, you talked about the event we had last Thursday, which is hard to believe that was two days ago or working days ago. The scale of Ulixa is disproportional to anything else. Once again, I mean no disrespect to AbbVie and others that were in our list last week as companies that did incredibly well, but the giants always stand on the shoulders of when we think about CNS.

As we're seeing more and more CNS companies moving into going back to these massive markets, that we're happy to be one of the most advanced ones. I think we are thrilled today, of course. There were times that we're having conversations like this that we were like, "Oh, do people even understand what essential tremor is? Do people even understand what SCN2A is?" You name it. We're no longer there, right? We're at the point that I think you and your colleagues did a lot of work to understand these markets. Ironically, I may say, a lot of people are coming back to us and saying, "Well, when you put $10 billion last year as the potential, no one really believed this." Now we're getting questions as why we were conservative with that, which I could never imagine I would get, to be honest.

But it doesn't stop there. You might recall probably one of our first conversations in our past lives here in terms of what we are doing today. You talked about how big of an activity this can be, as a company. I said, "That's not what we are focusing on at that point in time." To be honest, today, I think we're focusing on and to look into areas of biology and medicine that can make a real difference, and that have a real value on the other side. But it has to first make a difference, and then the value will follow. We announced last week that we're doing three extension studies for ulixacaltamide hydrochloride, one in restless legs syndrome, one in Parkinson's disease, and one in autism spectrum disorder. They're all starting pretty soon.

I think Parkinson's is the obvious, if I may, and for all of you, not obvious—

Joon Lee
Biotech Analyst, UBS

Is it Parkinson's disease or parkinsonism?

Marcio Souza
CEO, Praxis Precision Medicines

Yeah, it's Parkinson's tremor—

Joon Lee
Biotech Analyst, UBS

Okay.

Marcio Souza
CEO, Praxis Precision Medicines

—the way we're looking into this, which is a very, very large number of

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—Parkinson's patients. It's actually normally how we think about Parkinson's first, right? Then it progress. There was this impression that, "Oh, we know it's actually that is not that big of a deal." And the more work we've done, it's actually a huge deal for these patients. It's one of the most debilitating complex disease, but an expansion there. Restless legs, I think it goes without saying, I'm sure a bunch of people in this audience has it. It's such a prevalent condition. Great drugs are currently approved, but unfortunately, they lead to very quick, not only loss of effect, but worsening of effect while we stay on drug with the current treatment, so augmentation. It's probably the riskiest clinically of problems that we decided to go in, but it's a classical dislocated risk-reward perspective. And then maybe the last obvious that we discussed last week is ASC.

There is really tons of very good work done pre-clinically by independent researchers on that. It makes scientific sense, and soon enough, it's going to make clinical sense to all of you once we start. I can keep going on and on because there are 21 of those, but maybe you can talk about

Joon Lee
Biotech Analyst, UBS

Yeah. Let's do this very methodically. First things first. You had a late cycle meeting with the FDA.

from the meeting gives you confidence on the approval? Because it needs to be approved first.

Marcio Souza
CEO, Praxis Precision Medicines

Yeah.

Joon Lee
Biotech Analyst, UBS

What's the—

Marcio Souza
CEO, Praxis Precision Medicines

Everything about the meeting gives us confidence, and I don't say that lightly. I think everyone's like, "Oh, I cannot speak for the FDA," and I cannot speak for the FDA, so it goes without saying that that's not what I'm trying to do here. But we all done this for a bit, a minute or two, and there are elements, and I would say the three elements, in my view, that are important in meetings like this is, one, is leadership engagements on the agency sides, how much they understand the application, how willing they are to engage in these conversations. And while we had that from the get-go, from the very beginning, I think it was incredibly strong on this meeting. I think the second has to be the formal communication, right?

It's whether or not there are some things significant that they're still looking into, there are significant questions, and that goes with the tone of the meeting as well. And without going into absolute details, because we didn't really disclose these details, what I can say is that it felt a lot more like a label discussion than a late-cycle discussion. And, of course, that is incredibly important for us. This was not the least controversial application in history of application, right? We all had many debates about aspects of applications that people not even know exists. But it was always very clear, and I'm going to just remind everyone, this is not a change in tone. From the pre-NDA meeting, what we talked about was engagement, understanding of the program, understanding of the unmet needs, certainty of the data.

We just so happened that 10 months in the future from that day, at that point, and a little bit more now, we are in this position that the certainty of getting approved is incredibly high.

Joon Lee
Biotech Analyst, UBS

No, I mean, it is not without some drama during the clinical program, but you did get Breakthrough Therapy Designation after phase III. They looked at the data, which was unusual, and they filed it. Meetings are going well. Are there any other meetings scheduled between now and January 29, the PDUFA?

Marcio Souza
CEO, Praxis Precision Medicines

No, that is it. They are obviously expect, since we did not say when the meeting was.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

I am going to give them more overall PDUFA-based regulatory. We have to agree on possible PMCs and PMRs, of course, and then final label agreements, and things like that. But that is it, really, and hopefully the latter.

Joon Lee
Biotech Analyst, UBS

You are good on CMC and all those check-the-box stuff?

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. The point we—

Joon Lee
Biotech Analyst, UBS

Sites have been inspected.

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. The point we made from the beginning was unusual, right? Joon, we talked about this before, when you had some setbacks last year. I think a lot of people have deprioritized the program, not spending any money on CMC, not spending any money on other things. We decided that the risk-reward here was so positive on the side of if we were right and the study was positive, that we continue doing all the CMC activities. We had a Type C meeting with the agency. We discussed all the stuff. This is way before even the results, yeah, will lead us to be in a situation that right now we have a significant amount of inventory, which is important. I think Megan and Carl always tells me it is never enough, so we always make a little bit more.

We have dual manufacturing capacity for most of the process, but we're talking about metric tons of material, not talking about kilograms of material. That requires a lot of certainty, of course.

Joon Lee
Biotech Analyst, UBS

Yeah. A key component of the late-cycle meeting that gave you conviction is that it felt like more like a labeling discussion. What about the labeling discussion. It obviously included some DEA scheduling. I think it's very common for any CNS drug to do human abuse potential trial, and maybe it fell into maybe something that could be scheduled. Just tell us a little bit about that and anything else about the labeling in terms of how will it reflect the inclusion and exclusion that you had. What were they, or is it very broad. What are you expecting from the label.

Marcio Souza
CEO, Praxis Precision Medicines

Unexpectedly, from the development program perspective, I think if you go back to September 2023, a few years back, we were having a discussion with the agency about, do we believe there are certain subgroups of patients with essential tremor that could benefit better from this drug. To be perfectly honest, at that point in time, we didn't know. We had some ideas. In a very wise move, they told us, "We don't know enough about the epidemiology here. You should go for the broadest possible, and you're going to work with you if that end up being that one of those segments are not quite there." It was a little risky, as you can imagine, because essential tremor, by definition, is essential, so we don't know where it's come from. But we did, and as you know, by our results, no subgroup was inferior to placebo.

Was not even close. They all were statistically superior to placebo nominally. That is easy enough. The other thing is that the inclusion criteria, which became a common thing—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—in label for our studies, was really just adults with essential tremor. We went yes, we want to make sure their overall health was okay to participate on a clinical study, but had nothing to do with certain conditions. So there is no real restriction there. When you think about classical restrictions in label, age, special populations, well, age by definition here is a special population because it's a geriatric population. There's no pediatric expectation for this drug, renal, hepatic—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—these other things that should be pretty clean. On the DDI perspective, which sometimes restrict labels as well, like we have a CYP3A4 primary metabolism, so we did all the appropriate studies and we don't believe there's going to be any restrictions there either. No contraindications, no black box, no REMS. So, I don't know what could be a restriction. You tell me.

Joon Lee
Biotech Analyst, UBS

DEA Schedule IV or V. What's your base case?

Marcio Souza
CEO, Praxis Precision Medicines

My scientific base case and my belief science base case are not the same, right?

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

I think if you were pre-opioids epidemic, this drug would not be scheduled, in my humble view. It does not meet any criteria, structural or animal-related behavior. On the human abuse potential study, it shows some preference at the lowest dose, and then that disappears in higher dose, which is the opposite of what drug addicts tends to want. As a member of the public as well, not only drug developer, I think the FDA should take a conservative approach. Our view is that it is likely to be scheduled.

Phentermine was the control in the HAP study. That is a Schedule IV drug. So it could be Schedule IV, could be Schedule V, could be no scheduling. It does not matter. From a launch perspective, there is really no difference for us. Our target audience are neurologists.

They are very, very used to prescribe this drugs.

Joon Lee
Biotech Analyst, UBS

Before we move on to commercial aspects, you are not finalizing. The labeling conversations have not yet finalized. Is there a meeting for that separately between now and PDUFA?

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. I think we always have to hold our breath until the very last—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—minute on things like that. There's no indicators that would have any issue. That's maybe what I was trying to communicate before. There's nothing really that could narrow more the label than we see. There's no clinical indication that it should, safety. As you know, this was a population that going in, we were cautious. It's like an older population, and stuff happens when you are 75 years old, 80 years old, more so than when you are younger. But it's a very clean, safe profile as well.

Joon Lee
Biotech Analyst, UBS

Okay. Now, bulk of the investor event a few days ago were around your commercial strategies, and it's a massive opportunity. It's a very generalist opportunity, primary care physicians. You provided some pricing comps, launch comps. One slide that I found really interesting was a graph showing your typical launch curve, and a curve that looks like, if you focused on quantity, the peak kind of, I don't know, it's like your top peak kind of is lower.

If you focus on quality, it's a little bit more gradual, but actually the peak is much higher. Where is that coming from? Is that based on your intuition or anything based on data, evidence? Tell us about what that is and how you are going to focus on quality as opposed to quantity to get the maximum NPV.

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. We don't go to psychics for that. It's not intuition. That might be useful, but we haven't done it. We try to be very analytical.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

about all of this, and there are thankfully tens of recent launch that we can look into. I think sometimes company, and there's nothing wrong about that, are a little bit skewed towards pleasing Wall Street in the short run versus actually thinking about what their strategy in the long run is. We didn't talk about this, but I want to bring it up. We know that when you take this drug the first time, it's pretty rough for a proportion of the patients. It's incredibly potent drug. It gets a lot in the brain, and the thalamus is incredibly important, and it coordinates a lot of activity, and people do feel like dizzy, brain fog. We also know that if we keep them on drug, if we keep them longer for on 20 milligrams, that goes away. Controlling that experience controls a lot of things in the launch.

We put an incredible amount of emphasis on controlling experience. It is harder to control experience with volume, and that's why we're talking about quality being a combination of those two things. You want to drive a lot of demands, but also want to make sure that demand's coming from somewhat in a controlled phase. Every percent points, as Eric illustrated last week, on this drug for market share is about $1 billion. When you have a situation like that, you want to preserve early and late on all of them.

We would look into metrics, we look into launches that were done really, really well, and then dissect them, and ask the question, right? Did they generate enough demand? Did they generate enough coverage? I think what became common, and I'm going to call it unfortunate in some of the launches. Right now, that is, I'll take a little quick detour. Used to be that a few years back, we'd say small and mid-sized companies should not launch drugs like this, because the performance on the launch was pretty abysmal, right, when you compare to larger companies. It's no longer the case, and maybe I should write a piece about it. It's actually very clear that the gap basically disappears right now. It gives a lot of confidence.

I think it disappeared for the reason that more and more people are doing what we are doing, that is asking the market, instead of investing the minimum at launch, let's invest the ideal plus, right? Let's give them margin to be wrong. We are putting a significant amount of resource on this launch, including covering the entire prescribing base versus a fraction of the prescribing base. We can generate the maximum demand and control the experience.

That's how we see this market being closer to $30 billion than to $10 billion.

Joon Lee
Biotech Analyst, UBS

$30 billion?

Marcio Souza
CEO, Praxis Precision Medicines

That's what I said last week, that's why I am comfortable. It is at $36 billion, actually.

Joon Lee
Biotech Analyst, UBS

All right. One of the new data that you shared a couple days ago was the long-term—

Marcio Souza
CEO, Praxis Precision Medicines

Yeah.

Joon Lee
Biotech Analyst, UBS

—efficacy data, which I was really encouraged by, because initially, when you look at just one of the studies, actually, parallel comparator efficacy, I wasn't sure if it was durable beyond the 12 weeks, but you followed them for two years now almost, and I'm assuming that it's a combination of study one and two that you showed durability out to get that number. It's quite durable. That bodes well for, I guess, people who use it indefinitely. It's not like something you would use for just a year, or how do you see this being used in real world?

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. We used to get this question a lot.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

Right? It's like, "What happened?" As you might recall, there was a 12-week study, every other week for the first 49 days, then every week after that. It varies, right? If you measure the moods in this room every other week, then you look into the XBI, there's probably a correlation. But it varies even beyond that. It varies for these patients as well. I think the conspiracy theorists out there start saying, "Oh, no, it's actually fading. It's not varying." It was important for us, actually more for you guys than for us, but it was important to actually go way in the future then ask the question, well, if that's true, then everyone went back to baseline, or maybe some of them even got worse.

What you've seen on that data, there is even more data that you're going to see soon, hopefully even more data early in January as we complete. Our goal is to have about 200 patients with two years of follow-up or so, that is actually getting better to a point. Now, did it get better one year then stabilize, or we don't know.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

Right? We don't know what we don't know. But when you're talking about six, 6.5 point gain.

From with 12, imagine gaining six additional—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—functions during two years when natural history is losing additional functions at that time.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

If we did the, what is very common these days, propensity score matching, blah, blah, that would probably be like 8 or 10 points, right? That's the difference there. But we don't need it, right? Because it's actually very, very clear.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

Hopefully that went too bad, that discussion. This is a chronic treatment. Unfortunately, there's no cure for essential tremor. I wish there was one, but that is not the case. Patients progressively suffer. They lose function. That is something we're very committed to keeping them as long as possible.

Joon Lee
Biotech Analyst, UBS

Sounds good. Very quickly, you have Praxis Horizon set up to help facilitate the commercial uptake. Tell us a little bit about this program and how it's going to help prescribers and patients.

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. This is the craziest, most innovative program that ever been done here, and I think everything that is incredibly innovative has to be a little crazy. That is why I used the word first. Our ambition with the partners that they won was that we would really integrate all areas of the prescription process, all the way to reimbursements. You can imagine how a bunch of people told us that could not be done.

I am glad to say, and it is probably the first time we are saying this, actually, it has been done. It is operational right now. We run test scripts through it, beginning to end. It is, in a sense, what a lot of us in this room and outside dreamed for many years, that we would finally be able to integrate from Rx to dispensing without having to keep transferring data and integrating and stuff like that.

What it gives to us is as close to a control on what is happening so we can intervene.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

What gives to physicians is the ability to actually just, in their EMR system, prescribe the drug and automatically transfer data for a PA, automatically transfer data for other things, which gives to us and insurers is the ability to actually route the prescription to the preferreds through our Praxis pharmacy. What was maybe not clear on the conversation last week is that we are actually bringing to a Praxis pharmacy.

For the ones of you that have access to prescription systems, like as licensed physicians, I hope you keep your license, so you might be able to do this. You can actually see it. You can look it up, and you are listed there. So, going to come through a single, basically, it is not really a portal, right? Single source, and then it is going to fall through that. Removing attrition on a market like this is fundamental. We hear from the latest drug launch in CNS is very recent, is from an acquisition that one of the drugs did not work, so you can figure that out, which one, that is abysmal, the number of pages they have to fill, and that a lot of physicians are getting discouraged for prescribing because it is so much paperwork.

We learn from things like that, and we try to fix it, and in this case, we believe we fixed it.

Joon Lee
Biotech Analyst, UBS

I am sure the busy primary care physicians and neurologists would appreciate you guys actually doing the work for them.

Marcio Souza
CEO, Praxis Precision Medicines

Yeah.

Joon Lee
Biotech Analyst, UBS

And dealing with the insurance. Then they would actually also appreciate you guys doing a lot of this—

Marcio Souza
CEO, Praxis Precision Medicines

Yeah.

Joon Lee
Biotech Analyst, UBS

—in between work. Now, I know that we have five minutes left. We can go a little bit over because we have time, because we have not even started talking about the other one, relutrigine. But this, as you said, as Steve said on the event, this is a bit of a GLP-1 moment because you have parkinsonism, restless legs, autism spectrum disorder, ataxia, and then transdermal patch. Just, without going through this individually, just when are we going to start getting data for these?

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. A lot of that next year, right?

Joon Lee
Biotech Analyst, UBS

Okay.

Marcio Souza
CEO, Praxis Precision Medicines

A lot of that we're going to see data next year already. As one of the slides, I encourage you to go and take a look at our websites. For the two new programs, we are in IND-enabling talks now, and the two new programs are like next generation, Ulixa. That's one simple way to look into this. We advanced them quite nicely. We think they have slightly different properties that might expand the markets. That's relatively early in the year. From the Remagine collaboration, or what we call the patch, active delivery through the skin. So it's not a passive patch, right? So you literally, the physicians, the vision for that is a physician's office can modulate the titration remotely for these patients. And I can tell you all the electronics of that is sorted, all the current of that sorted.

We're just working with this current version of the engineering is locked, so we're really moving to the clinic next year. So, that is advancing incredibly fast.

Joon Lee
Biotech Analyst, UBS

Right.

Marcio Souza
CEO, Praxis Precision Medicines

We're not thinking about replacement with that, right? This is expansion.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

Now, maybe the part that people are still missing about the life cycle management for Ulixa or for the T-type calcium channel franchise is when you have a drug that can be used in multiple indications, but even if it couldn't, it's going to be used on millions and millions of patients.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

We have an obligation to actually expand other avenues, and that's what we are doing.

Joon Lee
Biotech Analyst, UBS

The whole biology of this T-type calcium channel and the rhythmicity and maybe the centrality of this mechanism in setting the tone for the rest of the body and the brain is really interesting. We'll go through that maybe over dinner, or wine. Let's move on to relutrigine. You have another PDUFA coming up. Quickly, what's the opportunity there?

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. The opportunities for there are two, right? We have a PDUFA coming up in about a month or so, a little bit over a month, for SCN2A and SCN8A, intractable encephalopathies, developmental encephalopathies. Incredibly sad, as you can imagine, these patients go through not being able to control their seizures at all to dying at about 18 years of age. This is not your classic, easy to control epilepsy at all. That is the first one. We believe that would be quite a large indication. What is quite interesting about relutrigine is it can be used and will be used, hopefully, in a much larger population, right?

It makes me incredibly happy with the fact that we have now us, I will give a shout-out to the work Lundbeck is doing as well as bexicaserin there, multiple companies actually developing drugs for this population that was neglected for a very long time. I am quite confident, and I wish they are successful as well, and their results coming up soon, because both drugs, there are 300,000 patients in the United States with this condition. The idea that someone needs to win is just completely insane. We are very excited about being the first.

I think we are very excited as well about having others playing on this space. The market, depending on how we look, it is around $5 billion-$8 billion peak total.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

Incredibly interesting as well.

Joon Lee
Biotech Analyst, UBS

Quickly, the PDUFA for SCN2A and SCN8A, are you still confident that they are going to meet the deadline given the recent additional

Marcio Souza
CEO, Praxis Precision Medicines

That is the indication they gave us.

Joon Lee
Biotech Analyst, UBS

Okay.

Marcio Souza
CEO, Praxis Precision Medicines

I think I'm less confident on the stage of the conversations, as I mentioned last week, than with Ulixa. I think Ulixa was as straight of a line as it gets to the approval. I think with Relu, for whatever reason, they were a little bit behind and then still working through it. I don't think, you know us, we're incredibly transparent as a company. I think we had a comparison between the two, and we were like, "Okay, Ulixa is clearly closer.

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

The unmet needs is very similar, maybe even higher on Relu, so I believe they're going to figure it out, but it felt a little bit more behind than Ulixa.

Joon Lee
Biotech Analyst, UBS

The timing of the EMERALD trial in broader DEEs, are you still on track for Q4, or could it slip into Q1, or what's the timing there?

Marcio Souza
CEO, Praxis Precision Medicines

When you get to the very, very end, that's the situation we're in, right? Where it's November, so 4Q is coming—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—approaching the end pretty quickly. The overall power shifts from our hands to how fast PIs are going to finish

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—unlocking the forms and making sure there are all the signatures and everything else. While we're pretty confident that it's all going to happen pretty quickly and we're going to be able to read out the certainty, there's always a small—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—there. I'm sure you would not appreciate that I stop your Christmas dinner to announce that. So, that is a point in the year that does not make sense anymore, but we're doing everything we can to actually get this year.

Joon Lee
Biotech Analyst, UBS

When was the last patient last visit for EMERALD?

Marcio Souza
CEO, Praxis Precision Medicines

A while back.

Joon Lee
Biotech Analyst, UBS

A while back.

Marcio Souza
CEO, Praxis Precision Medicines

Yeah. But that is safety, follow-up—

Joon Lee
Biotech Analyst, UBS

Yeah.

Marcio Souza
CEO, Praxis Precision Medicines

—things like that, right? We own that. It is a large study for DEEs, about 200 patients, right? It is a large number of sites, multiple countries. It takes a while to finalize it.

Joon Lee
Biotech Analyst, UBS

All right. We are out of time, and we did not even get a chance to talk about vormatrigine, but thank you so much for your time, Marcio, and thank you, everyone.

Marcio Souza
CEO, Praxis Precision Medicines

Thank you.